
Legislative progress in 25 states has mandated biomarker testing coverage, yet many patients still face prohibitive cost-sharing requirements and frequent insurance denials for innovative modalities. The promise of precision medicine—the tailoring of medical treatment to the individual
Cancer reported in nine Zolgensma recipients is drawing fresh attention to a concern that gene therapy has faced for years. The FDA is investigating the cases, but says Zolgensma’s benefits still outweigh the possible risks when used as approved. For families and companies developing similar
A strategic collaboration between Orbis Medicines and Novo Nordisk is currently focused on finding oral solutions for metabolic and cardiovascular diseases. This partnership signifies a broader shift in the biotechnology landscape, where the historical reliance on painful injections for chronic
The predictive accuracy of breast cancer treatment outcomes is being improved through the integration of advanced mass spectrometry and machine learning algorithms. This breakthrough addresses the persistent challenge of HER2-positive breast cancer, a subtype known for its aggressive nature and
Individual stock selection in the biotechnology space requires a deep understanding of patent laws and the complex regulatory environment established by the FDA. While high-tech sectors might experience massive surges during periods of economic expansion, the healthcare industry offers a unique
The persistent challenge of balancing aggressive oncologic treatment with the preservation of a patient's fundamental physiological resilience has led to a significant paradigm shift in the management of advanced cervical cancer. For decades, concurrent chemoradiotherapy has remained the standard
The Notch signaling cascade serves as a critical intercellular communication system that regulates cell fate but is frequently hijacked to drive tumor growth and drug resistance. This evolutionarily conserved mechanism operates through juxtacrine signaling, which necessitates direct physical
Suboptimal enzymes have long been the industry standard because the technology to design specific target reactions from scratch was previously unavailable. This technical ceiling has restricted progress across the pharmaceutical and agricultural sectors for decades, forcing scientists to rely on
A structured evaluative framework is now necessary to standardize the assessment of plant-derived anti-inflammatory compounds and their therapeutic potential. Historically, the field of pharmacology has leaned heavily on natural products as the bedrock of discovery, yet the journey from a bioactive
The ethical use of healthy, full-term placental tissue provides a unique source of stem-like cells possessing vital immunomodulatory properties for patient safety, and this therapeutic approach has recently gained significant traction as a viable solution for one of the most stubborn challenges in
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109
ITCurated uses cookies to personalize your experience on our website. By continuing to use this site, you agree to our Cookie Policy